NVSEF Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of 26.48% compared to Novartis AG's net margin of -106.6%. Novartis AG's return on equity of 30.96% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -31.12%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 44.98%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.559, which suggesting that the stock is 44.11% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.3%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Novartis AG's net income of $3.6B is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Novartis AG's price-to-earnings ratio is 18.86x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.56x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of 26.48% compared to Novartis AG's net margin of 0.11%. Novartis AG's return on equity of 30.96% beat BeOne Medicines's return on equity of -11.54%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -31.12%. On the other hand BeOne Medicines has an analysts' consensus of $330.95 which suggests that it could grow by 31.26%. Given that BeOne Medicines has higher upside potential than Novartis AG, analysts believe BeOne Medicines is more attractive than Novartis AG.

Novartis AG has a beta of 0.559, which suggesting that the stock is 44.11% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.3%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than BeOne Medicines quarterly revenues of $1.1B. Novartis AG's net income of $3.6B is higher than BeOne Medicines's net income of $1.3M. Notably, Novartis AG's price-to-earnings ratio is 18.86x while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.56x versus 6.47x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Roche Holding AG's return on equity of 23.8%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -31.12%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 15.24%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.559, which suggesting that the stock is 44.11% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.358%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.3%. Roche Holding AG offers a yield of 3.45% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.86x while Roche Holding AG's PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.56x versus 3.69x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.